Roth Capital Has Pessimistic View of Electromed Q2 Earnings

Electromed, Inc. (NYSE:ELMD) – Investment analysts at Roth Capital dropped their Q2 2026 earnings per share estimates for shares of Electromed in a research note issued to investors on Wednesday, November 12th. Roth Capital analyst K. Bauser now forecasts that the company will post earnings of $0.25 per share for the quarter, down from their previous forecast of $0.27. Roth Capital currently has a “Buy” rating and a $36.00 target price on the stock. Roth Capital also issued estimates for Electromed’s Q3 2026 earnings at $0.25 EPS, FY2026 earnings at $1.05 EPS and FY2027 earnings at $1.25 EPS.

Several other analysts have also commented on the stock. Loop Capital set a $36.00 price target on shares of Electromed in a research report on Wednesday, August 27th. Lake Street Capital started coverage on Electromed in a report on Wednesday, August 27th. They set a “buy” rating and a $36.00 target price on the stock. Finally, Zacks Research downgraded Electromed from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $36.50.

Electromed Trading Down 4.1%

NYSE:ELMD opened at $25.27 on Friday. The company has a market capitalization of $211.66 million, a P/E ratio of 33.69 and a beta of 0.40. The firm has a 50-day moving average price of $24.62 and a two-hundred day moving average price of $22.00. Electromed has a twelve month low of $17.73 and a twelve month high of $35.56.

Insiders Place Their Bets

In other Electromed news, Director Andrew Summers sold 62,561 shares of the business’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $24.32, for a total value of $1,521,483.52. Following the completion of the transaction, the director directly owned 3,153 shares in the company, valued at approximately $76,680.96. The trade was a 95.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On Electromed

Several institutional investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. boosted its stake in Electromed by 0.9% in the 3rd quarter. Raymond James Financial Inc. now owns 58,838 shares of the company’s stock worth $1,444,000 after buying an additional 507 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Electromed by 0.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 190,103 shares of the company’s stock worth $4,667,000 after acquiring an additional 696 shares during the period. American Century Companies Inc. boosted its position in shares of Electromed by 3.1% in the second quarter. American Century Companies Inc. now owns 32,031 shares of the company’s stock worth $704,000 after acquiring an additional 969 shares during the last quarter. Spire Wealth Management boosted its position in shares of Electromed by 22.7% in the second quarter. Spire Wealth Management now owns 5,405 shares of the company’s stock worth $119,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey purchased a new stake in Electromed in the second quarter valued at approximately $32,000. 40.82% of the stock is currently owned by institutional investors and hedge funds.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.